Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.

Patrick MarcellinQing XieSeung Woon PaikRobert FlisiakTeerha PiratvisuthJörg PetersenTarik AsselahMarkus CornbergDenis OuzanGraham R FosterGeorgios PapatheodoridisDiethelm MessingerLoredana RegepGeorgios BakalosUlrich AlshuthPietro LamperticoHeiner Wedemeyer

Published in: PloS one (2020)

Sustained off-treatment immune control is achieved with peginterferon alfa-2a in a real-world setting. HBsAg clearance 3 years after completion of peginterferon alfa-2a can be predicted on the basis of on-treatment HBsAg kinetics.

Keyphrases

hepatitis b virus
replacement therapy
combination therapy
cross sectional